Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.53 |
| ▸ | MELK | Q14680 | 3/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28731618 | 1.00 | LRRK2 (0.53) | LRRK2MELKMAP4K4ROCK2ROCK1 | |
| SCHEMBL28731759 | 1.00 | LRRK2 (0.53) | LRRK2MELKMAP4K4ROCK2ROCK1 | |
| SCHEMBL27242871 | 1.00 | LRRK2 (0.53) | LRRK2MELKMAP4K4ROCK2ROCK1 | |
| SCHEMBL27242887 | 0.92 | MELK (0.54) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL22964081 | 0.92 | LRRK2 (0.52) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL27242868 | 0.92 | LRRK2 (0.52) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL29725409 | 0.92 | LRRK2 (0.52) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL22964053 | 0.92 | MELK (0.54) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL29725427 | 0.92 | MELK (0.54) | LRRK2MELKROCK2ROCK1GSK3B | |
| SCHEMBL27242873 | 0.92 | LRRK2 (0.52) | LRRK2MELKROCK2ROCK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | claimed |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-08 | — | — | US | claimed |
| EP-4010317-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | claimed |
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4010317-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | LRRK2 1015/4885MELK 1357/4885MAP4K4 185/4885 |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | LRRK2 1015/4885MELK 1357/4885MAP4K4 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.